HOME >> MEDICINE >> NEWS
Molecular mechanism underlaying anthrax infection described by UCSD School Of Medicine researchers

The mechanism by which inhaled anthrax disarms and evades the immune system, enabling the potentially lethal bacteria to rapidly spread throughout the body, has been described by researchers at the University of California, San Diego (UCSD) School of Medicine.

Published online Aug. 29 in Science Express, the website of the journal Science, the lab-culture research with mouse cells describe how a complex of Bacillus anthracis (anthrax) proteins called lethal toxin (LT) inhibits and destroys macrophages, the large white blood cells that act as the body's first defense against pathogens, and also disables the signaling mechanism triggering immune activation. This allows the bacteria to spread through the body unchecked by the immune system, resulting in rapid and potentially lethal anthrax infection.

When the bacterium (b. anthracis) is inhaled, its spores are surrounded by alveolar macrophages in the lung, the beginning stage of normal immune response. But instead of succumbing to the defensive assault, they survive and germinate within the cells, traveling with the macrophages in their normal sentinel duty throughout the body to the lymph nodes, and eventually into the bloodstream, ultimately leading to fatal systemic shock if treatment fails.

In order to understand how anthrax was evading the immune system, the research team led by Michael Karin, Ph.D., UCSD professor of pharmacology and American Cancer Society Research Professor, used a variety of lab tests to determine how LT caused cell death in mouse macrophage cells. They pinpointed a series of steps, and specifically inhibition of an enzyme (a protein kinase) called p38, that lead to macrophage death and prevent secretion of chemokines and cytokines, the signaling agents that alert the immune system to the presence of an invading pathogen.

According to Karin, these findings open the door for development of an antidote that could block the action of a specific toxin called leth
'"/>

Contact: Sue Pondrom
spondrom@ucsd.edu
619-543-6163
University of California - San Diego
29-Aug-2002


Page: 1 2

Related medicine news :

1. Molecular test predicts risk of breast cancer recurrence and who will benefit from chemotherapy
2. Jefferson and Molecular Targeting Technologies, Inc. scientists create vaccine for wildlife rabies
3. Molecular tailoring of chemotherapy with novel imaging techniques
4. Molecular clock genes influence metabolism of sugar and dietary fats
5. Data announced at ISHLT: Molecular testing proves effective in monitoring heart transplant rejection
6. Molecular analyses of leukemia patients suggest strategies for better treatments
7. Molecular test proves to be effective in measuring remission and relapse after cancer treatment
8. Molecular tag pinpoints which breast cancer tumors are most likely to spread
9. Molecularly targeted drug slows tumor growth in patients
10. Molecular self-assembly techniques used to coat biomedical substrates
11. Molecular nanogenerator developed that can target cancer cells and destroy them

Post Your Comments:
(Date:5/24/2013)... (PRWEB) May 24, 2013 Today marks ... all-new online Itinerary Builder. , The redesigned and ... create unique vacation itineraries on their computer or mobile ... , The interactive tool allows users to fill in ... browse through and select their choice of vacation packages, ...
(Date:5/24/2013)... American Fork, Utah (PRWEB) May 24, 2013 ... several years now and is excited to announce it’s new weight ... our product that we are offering our customers their money back ... says Dave Sherwin, CEO of HCG EZ Drops. “The HCG ... caloric intake; hence the 21 pounds in 21 days.” , The ...
(Date:5/23/2013)... Magnatag’s new magnetic 365-Day attendance and vacation monitor ... A Manufacturing Manager from Augusta GA told us, “We ... managers can check the board for themselves and we ... us and the board makes the record public so ... it has made a difference.” , “Our customers ...
(Date:5/23/2013)... FL (PRWEB) May 24, 2013 Internationally ... coaching educators in tennis for over 29 years, ... than 50 ATP & WTA players, Grand Slam winners, ... Italian Open Champions, 25 USTA National Junior Champions, 8 ... Junior Champions, including Sunshine Cup, Orange Bowl and Eddie ...
(Date:5/23/2013)... Orange County film studio and visual effects ... light leaks for Apple's Final Cut Pro X today. ... no longer have to worry about matching up the movement ... Said Christina Austin, CEO of Pixel Film Studios, "You have ... look." , ProLeak from Pixel Film Studios allows users to ...
Breaking Medicine News(10 mins):Health News:Create and Win the Perfect Halifax Getaway with the All-New Itinerary Builder 2Health News:New Attendance, Vacation and Training Tracker Board Reduces Employee Conflicts and Improves Attendance 2Health News:Internationally Respected Tennis Coach, Nick Saviano Opens Summer Training Registration 2Health News:Pixel Film Studios Releases ProLeak Light Leaks for Final Cut Pro X Today 2
(Date:5/23/2013)... TEL AVIV, Israel , May 23, 2013 ... of BrainTech Israel 2013 , Israel,s ... take place on October 14 th -15 th in ... 2 nd most innovative city in the world by ... the "Start-up Nation." BrainTech Israel 2013 will showcase ...
(Date:5/23/2013)... 23, 2013 Halozyme Therapeutics, Inc. (NASDAQ: ... of David A. Ramsay ... recently Vice President, Corporate Development at Halozyme. ... "With his established financial management experience and his ... in our commercial group for the last four ...
(Date:5/23/2013)... 2013  Omeros Corporation (NASDAQ: OMER ... Application (IND) to evaluate OMS824 in Huntington,s disease ... Drug Administration (FDA). OMS824 selectively inhibits phosphodiesterase 10 ... brain linked to a wide range of diseases ... OMS824 has shown promising results in animal models ...
Breaking Medicine Technology:Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 2Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 3Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4
Cached News: